Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0917798 (
cerebral ischemia
)
17,036
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Eukaryotic initiation factor (eIF) 4E-binding proteins (4E-BPs) are translational repressors that bind specifically to eIF4E and are critical in the control of protein translation.
4E-BP2
is the predominant 4E-BP expressed in the brain, but their role is not well known. Here, we characterized four forms of
4E-BP2
detected by two-dimensional gel electrophoresis (2-DGE) in brain. The form with highest electrophoretic mobility was the main form susceptible to phosphorylation at Thr37/Thr46 sites, phosphorylation that was detected in acidic spots.
Cerebral ischemia
and subsequent reperfusion induced dephosphorylation and phosphorylation of
4E-BP2
at Thr37/Thr46, respectively. The induced phosphorylation was in parallel with the release of
4E-BP2
from eIF4E, although two of the phosphorylated
4E-BP2
forms were bound to eIF4E. Upon long-term reperfusion, there was a decrease in the binding of
4E-BP2
to eIF4E in cerebral cortex, demonstrated by cap binding assays and
4E-BP2
-immunoprecipitation experiments. The release of
4E-BP2
from eIF4E was without changes in
4E-BP2
phosphorylation or other post-translational modification recognized by 2-DGE. These findings demonstrated specific changes in
4E-BP2
/eIF4E association dependent and independent of
4E-BP2
phosphorylation. The last result supports the notion that phosphorylation may not be the uniquely regulation for the binding of
4E-BP2
to eIF4E under ischemic stress.
...
PMID:Dissociation of eIF4E-binding protein 2 (4E-BP2) from eIF4E independent of Thr37/Thr46 phosphorylation in the ischemic stress response. 2582 52
